Now that twitter has recovered from its downtime, a catch-up tweetorial on apixaban for AF in patients on dialysis for you.
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
Now that twitter has recovered from its downtime, a catch-up tweetorial on apixaban for AF in patients on dialysis for you.
Many nephrologists make decisions about which anticoagulant (if any) to recommend for atrial fibrillation in patients on haemodialysis on a weekly basis.
— Nephrology Journal Club (@NephJC) March 6, 2023
And we finally have more randomised data!
Enjoy a rapid catch-up with #TenTweetNephJC pic.twitter.com/r99aAqPeiV